RxDoctor Payments DataLook up a doctor →

Christopher Disimone, MD

Hematology & Oncology · Scottsdale, AZNPI 1861461147

Payments from drug & device makers

$2,748,703in general payments, 2019–2025

Across 1,705 payments — averaging $1612.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$1.9M
  • Eli Lilly$229K
  • E.r. Squibb & Sons, L.L.C.$142K
  • Astellas Pharma Global Development$127K
  • Seagen Inc.$115K
  • Bristol Myers Squibb$85K
  • plus $141K from 53 others
$13,655in research payments, 2019–2025

Across 3 payments — averaging $4551.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$12K
  • Pfizer$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.1,074$1,908,453
Eli Lilly5$229,462
E.r. Squibb & Sons, L.L.C.41$142,295
Astellas Pharma Global Development12$127,154
Seagen Inc.117$114,948
Bristol Myers Squibb11$85,339
Pfizer56$55,183
Incyte Corporation66$25,098
Gilead15$16,386
Merck65$15,493
Janssen Research & Development, LLC9$10,693
Genentech, Inc.3$6,580
AstraZeneca(2 entities)21$4,859
Astellas Pharma US Inc9$1,559
Acerta Pharma LLC1$1,250
Amgen41$567
Johnson & Johnson18$364
Novartis16$327
Daiichi Sankyo Inc.16$314
Genentech USA, Inc.15$263
Lilly USA, LLC9$204
Bayer6$125
GSK5$116
Pharmacyclics LLC, An Abbvie Company5$108
Puma Biotechnology, Inc.5$99
Stemline Therapeutics Inc.4$89
Sanofi5$88
Springworks Therapeutics, Inc.3$87
Takeda Pharmaceuticals U.S.A., Inc.4$81
AVEO Pharmaceuticals, Inc.2$79
Regeneron Healthcare Solutions, Inc.2$72
Blueprint Medicines Corporation3$63
ADC Therapeutics America, Inc.2$59
Array Biopharma Inc2$59
Boehringer Ingelheim3$54
CTI Biopharma Corp.2$53
AbbVie2$52
Beigene USA, Inc.2$49
Karyopharm Therapeutics Inc.2$45
Sobi, Inc2$41
Regeneron1$41
Kyowa Kirin, Inc.2$39
Pharmacosmos Therapeutics Inc.2$37
Servier Pharmaceuticals LLC2$35
Sun Pharmaceutical Industries Inc.2$35
Tersera Therapeutics LLC1$30
Cardinal Health 414 LLC1$29
Rigel Pharmaceuticals, Inc.1$27
Clovis Oncology, Inc.2$27
Tempus AI, Inc1$25
Lexicon Pharmaceuticals, Inc.1$22
Fresenius Kabi USA, LLC1$22
Mirati Therapeutics, Inc.1$20
Alnylam Pharmaceuticals Inc.1$20
Coherus Oncology, Inc.1$19
Exelixis Inc.1$18
Cumberland Pharmaceuticals, Inc.1$16
EMD Serono, Inc.1$16
Agios Pharmaceuticals, Inc.1$16

How this compares

$2,748,703 in reported general payments places this provider in the 90th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$170,884
Medicare patients
296
Services billed
1,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →